Bortezomib powder is formulated for injection. It is a member of the proteasome inhibitor medication class and is primarily used to treat the blood malignancy multiple myeloma. This substance functions by preventing the functioning of proteasomes, cellular organelles that assist in breaking down proteins. Bortezomib powder causes the death of cancer cells by impairing their ability to function normally by blocking the proteasomes. In order to create an injection-ready solution, it is routinely reconstituted with an appropriate diluent. In a hospital or clinic setting, a healthcare worker administers it intravenously. Our drug is a proteasome inhibitor that is recommended for treating adult multiple myeloma patients.